-- IPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical
update and Trial In Progress presented at AACR Annual Meeting 2025 and
ASCO 2025 Annual Meeting.
-- Lacutamab BTD and Phase 3 preparation: FDA Breakthrough Therapy
Designation (BTD) in February 2025 based on long-term follow-up data from
the TELLOMAK clinical study presented at ASCO Annual Meeting 2025.
Preparation of the confirmatory Phase 3 trial protocol is close to
completion, following discussions with the FDA and EMA.
-- Monalizumab: AstraZeneca Phase 3 PACIFIC-9 enrollment is completed and
high level read-out is expected in H2 2026.
-- Strategic focus: Innate Pharma plans to prioritize its investment in
what it believes are its highest-value clinical assets, IPH4502,
lacutamab, and monalizumab (partnered with AstraZeneca); its preclinical
research and development (R&D) efforts will focus on advancing the next
ADCs toward development, leveraging its pipeline of innovative targets.
In line with such strategic focus and its objectives, the Company intends
to streamline its organization. Staffing levels are expected to decrease
overall by about 30%.
-- Corporate update: Eric Vivier has decided to return to academic
research full-time, and he will continue to support the Company's
innovation as an advisor to the R&D Committee of the Board of Directors.
As Chief Operating Officer $(COO)$, Yannis Morel will continue to be
responsible for preclinical research and development, and will assume
Chief Scientific Officer (CSO) responsibilities.
-- EUR15m equity investment by Sanofi in April 2025, in addition to the
ongoing partnership with Sanofi, which includes the development of the
BCMA targeting ANKET$(R)$ program in autoimmune indications.
-- Cash position of EUR70.4 million1 as of June 30, 2025, anticipated cash
runway until end Q3-2026.
-- Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT.
MARSEILLE, France--(BUSINESS WIRE)--September 17, 2025--
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the six months ended June 30, 2025. The consolidated financial statements are attached to this press release.
"With key milestones anticipated over the next 12 months, our primary focus will be on progressing what we believe are our most promising and highest-value clinical assets and advancing our next ADCs toward development. In line with this strategic focus and in a challenging funding environment, we are taking necessary action to focus our resources on what we believe are the programs with the highest potential to deliver value for both patients and shareholders, and we therefore plan to streamline the size of the organization," said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. "We made meaningful progress during the first half of the year in our pipeline and are determined to build on this momentum. At ASCO, we presented a Trial In Progress for our Nectin-4 ADC, IPH4502, which is progressing rapidly through Phase 1 enrollment; and we shared long-term follow-up data for lacutamab, for which preparation of the confirmatory Phase 3 trial protocol is close to completion, following discussions with the FDA and EMA. Looking ahead, we have a number of important catalysts, including first patient data for IPH4502 in H1 2026, and high level read-out of AstraZeneca's PACIFIC-9 Phase 3 trial with monalizumab in H2 2026."
____________________
(1) Including short term investments (EUR6.3 million) and non-current
financial instruments (EUR10.4 million)
Webcast and conference call will be held today at 2:00 p.m. CEST (8:00 a.m.
ET)
Access to live webcast: https://events.q4inc.com/attendee/642492835
Participants may also join via telephone using the registration link below:
https://registrations.events/direct/Q4I970472
This information can also be found on the Investors section of the Innate
Pharma website, www.innate-pharma.com.
A replay of the webcast will be available on the Company website for 90 days
following the event.
------------------------------------------------------------------------------
Pipeline highlights:
Strategic focus
Innate Pharma plans to prioritize its investment on what it believes are its highest-value clinical assets, IPH4502, lacutamab, and monalizumab (partnered with AstraZeneca); its preclinical research and development (R&D) efforts will focus on advancing the next Antibody Drug Conjugates (ADCs) toward development, leveraging its pipeline of innovative targets.
IPH4502 (Nectin-4 ADC, proprietary):
IPH4502 is Innate's novel and differentiated topoisomerase I inhibitor ADC targeting Nectin-4.
-- The first patient was dosed in a Phase 1 study in January 2025. The
Phase 1 study will assess the safety, tolerability, and preliminary
efficacy of IPH4502 in advanced solid tumors known to express Nectin-4,
including but not limited to urothelial carcinoma, non-small cell lung,
breast, ovarian, gastric, esophageal, and colorectal cancers. The study
plans to enroll approximately 105 patients. A Trial in Progress Poster
was shared at the ASCO Annual Meeting in June 2025. Enrollment is in
progress and expected to be completed at the end of 2025 or in the first
quarter of 2026.
-- New preclinical data were presented at the American Association for
Cancer Research (AACR) Annual Meeting 2025. IPH4502 demonstrated superior
preclinical anti-tumor activity compared to enfortumab vedotin (EV) in
urothelial carcinoma (UC) models with low or heterogeneous Nectin-4
expression, as well as in models resistant to EV. Beyond UC, IPH4502 also
exhibited anti-tumor activity in preclinical models of triple-negative
breast cancer, head and neck squamous cell carcinoma, and esophageal
cancer, suggesting broader potential clinical applicability.
Lacutamab (anti-KIR3DL2 antibody, proprietary):
Cutaneous T Cell Lymphoma
-- In February 2025, the FDA granted Breakthrough Therapy Designation to
lacutamab for relapsed or refractory Sézary syndrome (SS) based on
TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety
profile in patients with advanced SS, heavily pretreated,
post-mogamulizumab. Breakthrough Therapy Designation is intended to
accelerate the development and regulatory review in the U.S. of drugs
that are intended to treat a serious condition.
-- At the 2025 ASCO Annual Meeting, updated long-term data from the Phase
2 TELLOMAK trial reinforced the clinical activity and durability of
lacutamab in relapsed/refractory SS and mycosis fungoides (MF). In SS,
lacutamab achieved a 42.9% ORR with a median duration of response of 25.6
months, while in MF, responses were observed regardless of KIR3DL2
expression, with a median PFS of 10.2 months. Across both cohorts,
lacutamab was well tolerated, with no safety concerns and sustained
improvements in quality of life.
-- Preparation of the confirmatory Phase 3 trial protocol is close to
completion, following discussions with the FDA and EMA. Innate is
evaluating potential paths forward to advance lacutamab toward Phase 3
initiation, including discussions with partners and investors.
Peripheral T Cell lymphoma (PTCL)
-- The Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an
investigator-sponsored, randomized controlled trial, led by the Lymphoma
Study Association, to evaluate lacutamab in combination with GEMOX
(gemcitabine and oxaliplatin) chemotherapy versus GEMOX alone, in
patients with KIR3DL2-expressing relapsed/refractory PTCL, is ongoing and
continues to recruit patients.
Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca:
-- The Phase 3 PACIFIC-9 trial run by AstraZeneca evaluating durvalumab
(anti-PD--L1) in combination with monalizumab or AstraZeneca's oleclumab
(anti-CD73) in patients with unresectable, Stage III non-small cell lung
cancer (NSCLC) who have not progressed following definitive
platinum-based concurrent chemoradiation therapy $(CRT)$ is ongoing.
Enrollment in the trial is completed, and high level read-out is expected
in H2 2026.
-- At the ASCO Annual Meeting in June 2025, AstraZeneca presented updated
results from the Phase 2 NeoCOAST-2 trial evaluating neoadjuvant and
adjuvant durvalumab-based combinations in resectable NSCLC. The regimen
including durvalumab, monalizumab, and chemotherapy (Arm 2, n=70) showed
25.7% pathological complete response (pCR) and 50.0% major pathologic
response (mPR).
ANKET(R) (Antibody-based NK cell Engager Therapeutics):
ANKET(R) is Innate's proprietary platform for developing next-generation, multi-specific NK cell engagers to treat certain types of cancer.
IPH6501 (ANKET(R) anti-CD20 with IL-2V, proprietary)
-- The Phase 1/2 clinical trial is evaluating IPH6501 in B-cell
Non-Hodgkin's lymphoma (B-NHL). The study is planned to enroll up to 184
patients. Clinical sites are open in the US, Australia, and France. The
dose escalation phase in the trial has been completed. Limited signals of
activity were observed during the escalation phase, and maximum tolerated
dose $(MTD)$ is currently being explored to further assess clinical
relevance. Clinical data are expected in late 2025 or beginning of 2026.
IPH6101 (ANKET(R) anti-CD123, proprietary)
-- Innate regained the rights to SAR'579/IPH6101 in July 2025. The Company
is in the process of receiving the product data from Sanofi relating to
the Sanofi-led Phase 1/2 study and Phase 2 preliminary dose expansion of
the trial.
SAR'514/IPH6401 (BCMA ANKET(R) , Sanofi)
-- As previously disclosed, Sanofi has opted to pursue the development of
SAR'514/IPH6401 (BCMA ANKET(R)) in autoimmune indications under the terms
of the 2016 License Agreement.
-- The Sanofi-led Phase 1/2 study (clinical study identifier: NCT05839626)
for the treatment of patients with relapsed or refractory multiple
myeloma has been terminated early, in line with the decision to focus
SAR'514/IPH6401 development in autoimmune indications.
Preclinical ANKET
-- IPH62 (partnered with Sanofi): IPH62 is an NK-cell engager program
targeting B7-H3 from Innate's ANKET(R) platform, which is under
preclinical development. Following a research collaboration period and
upon candidate selection, Sanofi will be responsible for all development,
manufacturing and commercialization.
-- Sanofi still retains an option on one additional ANKET(R) target under
the terms of the 2022 research collaboration and license agreement.
Other assets
-- IPH5201 (anti-CD39), partnered with AstraZeneca: The MATISSE Phase 2
clinical trial conducted by Innate in neoadjuvant lung cancer for
IPH5201, an anti-CD39 blocking monoclonal antibody developed in
collaboration with AstraZeneca, is ongoing, and recruitment is on track.
-- IPH5301 (anti-CD73): The investigator-sponsored CHANCES Phase 1 trial
of IPH5301 with Institut Paoli-Calmettes is ongoing.
Corporate Update:
-- Innate Pharma plans to prioritize its investment on what it believes
are its highest-value clinical assets, IPH4502, lacutamab, and
monalizumab (partnered with AstraZeneca); its preclinical research and
development (R&D) efforts will focus on advancing the next ADCs toward
development, leveraging its pipeline of innovative targets. In line with
such strategic focus and its objectives, the Company intends to
streamline its organization. Staffing levels are expected to decrease
overall by about 30% total, including through attrition. The planned
layoffs will be implemented through a redundancy plan that is subject to
consultation with the Workers' Council and endorsement by the French
authorities (Dreets). The implementation of the change is expected to be
completed during the first half of 2026.
-- Eric Vivier, CSO, has decided to return to academic research full time,
effective January 1, 2026, and he will continue to support the Company's
innovation as an advisor to the R&D Committee of the Board of Directors.
Innate will continue accessing innovation through academic collaborations,
including Eric Vivier's lab at the Center for Immunology of
Marseille-Luminy (CIML). As Chief Operating Officer (COO), Yannis Morel,
will continue to be responsible for preclinical research and development,
and effective January 1, 2026 will assume CSO responsibilities.
-- As announced on April 23, 2025, Sanofi and Innate agreed to terminate
the 2016 Research Collaboration and Licence Agreement (the "2016
Agreement") as it relates to SAR'579/IPH6101 (CD123 ANKET(R)). As part of
their discussions with regards to the review of the 2016 Agreement,
Sanofi and Innate announced the investment by Sanofi of up to EUR15
million in new shares of Innate. Sanofi then subscribed to 8,345,387 new
ordinary shares of Innate, at a price of EUR1.7974 per share,
representing a total capital increase of EUR14,999,998.59 (EUR417,269.35
in nominal amount and EUR14,582,729.24 of issue premium) representing
9.05% of Innate's total outstanding shares as of the time of such capital
increase.
-- On May 22, 2025, after approval at the Annual General Meeting, Innate
Pharma changed its corporate governance from an executive
board/supervisory board structure to a CEO/board of directors with Irina
Staatz-Granzer as Chairwoman and Jonathan Dickinson as Chief Executive
Officer. This transformation is part of the Company's strategic plan to
simplify and align its governance with international standards. As part
of the change, two seasoned biotech executives, Marty J. Duvall and
Christian Itin, joined the Board of Directors. In addition, a new R&D
Committee has been established as a committee of the Board of Directors,
the role of which is to analyze research and development opportunities
for the Company's products. Its members are Bpifrance Participations,
represented by Olivier Martinez, also appointed Chairman of the Research
and Development Committee, Véronique Chabernaud and Christian Itin.
-- As of June 30, 2025, the balance available under our April 2023 sales
agreement under the At-The-Market program remains at $75 million.
-- Stéphanie Cornen was appointed Vice President, Investor Relations,
Communications and Commercial Strategy after Henry Wheeler, VP Investor
Relations and Communications resigned from his position in order to
pursue another opportunity outside the Company. Stéphanie Cornen
joined Innate in 2012. Between 2012 and 2022, she held several R&D
positions, contributing to the advancement of programs across various
development stages. Starting in 2022, she took on responsibilities in
corporate development and portfolio strategy, while supporting investor
relations. Stéphanie Cornen holds a PharmD and a PhD from
Aix-Marseille University, as well as an Executive MBA from HEC Paris.
Financials highlights for the first half of 2025:
The key elements of Innate's financial position and financial results as of and for the six-month period ended June 30, 2025 are as follows:
-- Cash, cash equivalents, short-term investments and financial assets
amounting to EUR70.4 million (EURm) as of June 30, 2025 (EUR91.1m as of
December 31, 2024).
-- As of June 30, 2025, financial liabilities amount to EUR27.0m (EUR31.0m
as of December 31, 2024). This change is mainly due to loan repayments.
-- Revenue and other income amounted to EUR4.9m in the first half of 2025
(EUR12.3m in the first half of 2024) and mainly comprised of:
-- Revenue from collaboration and licensing agreements, which
mainly resulted from the partial or entire recognition of the
proceeds received pursuant to the agreements with AstraZeneca and
Sanofi. They are recognized when the entity's performance
obligation is met. They are recognized at a point in time or
spread over time according to the percentage of completion of the
work that the Company is committed to carry out under these
agreements:
-- (i) Revenue from collaboration and licensing agreements
for monalizumab decreased by EUR2.9m to EUR0.1m in the
first half of 2025 (EUR3.0m in the first half of 2024).
This change is mainly due to the progress of Phase 1/2
trials close to termination.
-- (ii) Revenue related to the license and collaboration
agreement signed with Sanofi in 2016 decreased by EUR4.0m.
These revenues are nil for the first half of 2025 as
compared to EUR4.0m for the first half of 2024. On April
15, 2024, the Company announced the treatment of the first
patient in the Phase 2 dose expansion part of the
Sanofi-sponsored clinical trial evaluating NK Cell Engager
SAR443579/ IPH6101 in various blood cancers. Under the
terms of the 2016 agreement, this trial progress triggered
a milestone payment of EUR4.0 million fully recognized in
revenue during the first quarter of 2024. This amount was
received by the Company on May 17, 2024.
-- (iii) Revenue related to the research collaboration and
licensing agreement signed with Sanofi in 2022 remained
constant over the period, with revenue amounting to EUR0.2
million for the first half of 2025, as for the first half
of 2024. As previously disclosed, on January 25, 2023, the
Company announced the expiration of the waiting period
under the Hart-Scott-Rodino (HSR) Antitrust Improvements
Act of 1976 and the effectiveness of the licensing
agreement as of January 24, 2023. Consequently, the Company
received an upfront payment of EUR25.0 million in March
2023, including EUR18.5 million for the exclusive license,
EUR1.5 million for the research activities and EUR5.0
million for the option on two additional targets. The
EUR18.5 million upfront payment relating to the exclusive
license was fully recognized in revenue as of June 30,
2023. The research work upfront payment is recognized on a
straight-line basis over the duration of the research
activities that the Company has agreed to carry out. On
December 19, 2023, the Company announced that Sanofi had
exercised one of the two license options for a new program
based on the Company's ANKET(R) platform. This decision
triggered a milestone payment of EUR15.0m, including
EUR13.3m for the exclusive license, fully recognized in
revenue as of December 31, 2023, and EUR1.7m for research
work to be carried out by the Company as well as the
recognition in revenue of an amount of EUR2.5m initially
received in March 2023 in connection with this option. On
October 9, 2024, the Company received a termination letter
for the license agreement concerning this option. The
termination ends the research work. The revenue of EUR1.7
million was therefore fully recognized as revenue on
December 31, 2024. Revenue from research work on the first
license amounted to EUR0.2 million for the first half of
2025. Amounts not recognized in revenue are classified as
deferred revenue.
-- Government funding for research expenditures of EUR3.2m in the
first half of 2025 (EUR4.1m in the first half of 2024), decreasing
by EUR0.9 million, or 21.3% in connection with decrease in
eligible subcontracting expenses following progress in studies and
research programs.
-- Operating expenses are EUR30.3m in the first half of 2025 (EUR38.7m in
the first half of 2024), of which 67.8% (EUR20.5m) are related to R&D.
-- R&D expenses decreased by EUR8.6m to EUR20.5m in the first half
of 2025 (EUR29.1m in the first half of 2024). This change is
mainly explained by direct R&D expenses, which slightly decreased
by EUR7.3 million or 43% to reach EUR9.7 million for the first
half of 2025. This decrease is related to the phasing of studies
(maturity of clinical studies on lacutamab, discontinuation of
preclinical studies, and start of phase 1 of our antibody-drug
conjugate $(ADC)$ program).
-- General and administrative (G&A) expenses increased by EUR0.2m
to EUR9.8m in the first half of 2025 (EUR9.6m in the first half of
2024) mainly resulting from an increase in personnel expenses
linked to provisions for risks and charges, bringing personnel
expenses to EUR4.8 million in the first half of 2025, offset by a
EUR0.5 million decrease in non-scientific and consulting fees,
which amounts to EUR1.4 million in the first half of 2025,
resulting mainly from greater use of recruitment agencies in 2024
(for the establishment of the clinical department), which was not
renewed in 2025.
-- A net financial gain of EUR4.1m in the first half of 2025 (EUR1.5m in
the first half of 2024). This change is mainly due to a favorable
variation in net foreign exchange gain with its favorable impact on the
collaboration liabilities recorded during the first half of 2025 in
connection with the change in the dollar exchange rate despite an
unfavorable variation in income resulting from financial assets and fair
value revaluation due to an unfavorable effect of investment rates
recorded on the financial markets.
-- A net loss of EUR21.3m for the first half of 2025 (net income of
EUR24.8m for the first half of 2024).
The table below summarizes the IFRS consolidated financial statements as of and for the six months ended June 30, 2025, including 2024 comparative information.
In thousands of euros, except for data per share June 30, 2025 June 30, 2024
Revenue and other income 4,860 12,345
Research and development expenses (20,520) (29,076)
General and administrative expenses (9,767) (9,582)
Operating expenses (30,287) (38,657)
------------------------------------------------ ------------- -------------
Operating income (loss) (25,427) (26,313)
------------------------------------------------ ------------- -------------
Net financial income (loss) 4,083 1,549
Income tax expense -- --
------------- -------------
Net income (loss) (21,344) (24,764)
------------- -------------
Weighted average number of shares ( in
thousands) : 86,937 80,872
- Basic income (loss) per share (0.25) (0.31)
- Diluted income (loss) per share (0.25) (0.31)
June 30, 2025 December 31, 2024
Cash, cash equivalents and financial assets 70,417 91,051
Total assets 92,937 111,059
Total shareholders' equity 5,144 8,834
Total financial debt 27,029 30,995
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its antibody-engineering expertise, the company has developed innovative therapeutic approaches, including Antibody Drug Conjugates (ADC), monoclonal antibodies (mAbs) and multi-specific NK Cell Engagers through its proprietary ANKET(R) (Antibody-based NK cell Engager Therapeutics) platform.
Innate's portfolio includes IPH4502, a differentiated Nectin-4 ADC in development in solid tumors, lacutamab, an anti-KIR3DL2 mAb developed in advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as renowned research institutions, working together to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.
Information about Innate Pharma shares:
ISIN code FR0010331421 Ticker code Euronext: IPH Nasdaq: IPHA LEI 9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including "anticipate," "believe," "can," "could," "estimate," "expect," "may," "might," "potential," "expect" "should," "will," or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Summary of Interim Condensed Consolidated Financial Statements and Notes as of JUNE 30, 2025
Interim Condensed Consolidated Statements of Financial Position
(in thousand euros)
June 30, 2025 December 31, 2024
-------------------------------------------- ------------- -----------------
Assets
Current assets
Cash and cash equivalents 53,704 66,396
Short-term investments 6,323 14,374
Trade receivables and others 4,951 4,972
Total current assets 64,978 85,742
Non-current assets
Property and equipment 4,955 5,133
Non-current financial assets 10,390 10,281
Other non-current assets 577 575
Trade receivables and others - non-current 12,036 9,328
Deferred tax asset --
Total non-current assets 27,958 25,317
Total assets 92,937 111,059
-------------------------------------------- ------------- -----------------
Liabilities
Current liabilities
Trade payables and others 12,041 16,007
Collaboration liabilities -- current portion 6,782 7,443
Financial liabilities -- current portion 8,934 8,709
Deferred revenue -- current portion 563 616
Provisions - current portion 1,106 207
Total current liabilities 29,426 32,982
Non-current liabilities
Collaboration liabilities -- non-current
portion 34,518 41,128
Financial liabilities -- non-current portion 18,095 22,286
Defined benefit obligations 2,666 2,730
Deferred revenue -- non-current portion 2,628 2,825
Provisions - non-current portion 460 274
Total non-current liabilities 58,367 69,244
Shareholders' equity
Share capital 4,610 4,192
Share premium 407,048 390,979
Retained earnings (386,364) (336,893)
Other reserves 1,194 27
Net income (loss) (21,344) (49,471)
Total shareholders' equity 5,144 8,834
Total liabilities and shareholders' equity 92,937 111,059
-------------------------------------------- ------------- -----------------
Interim Condensed Consolidated Statements of Income (loss)
(in thousand euros)
June 30, 2025 June 30, 2024
------------------------------------------------ ------------- -------------
Revenue from collaboration and licensing
agreements 1,671 8,293
Government financing for research expenditures 3,189 4,052
Revenue and other income 4,860 12,345
------------------------------------------------ ------------- -------------
Research and development expenses (20,520) (29,076)
General and administrative expenses (9,767) (9,582)
Operating expenses (30,287) (38,657)
------------------------------------------------ ------------- -------------
Operating income (loss) (25,427) (26,313)
------------------------------------------------ ------------- -------------
Financial income 6,886 3,613
Financial expenses (2,803) (2,064)
Net financial income (loss) 4,083 1,549
------------------------------------------------ ------------- -------------
Net income (loss) before tax (21,344) (24,764)
------------------------------------------------ ------------- -------------
Income tax expense -- --
Net income (loss) (21,344) (24,764)
------------------------------------------------ ------------- -------------
Weighted average number of shares : (in
thousands) 86,937 80,872
- Basic income (loss) per share (0.25) (0.31)
- Diluted income (loss) per share (0.25) (0.31)
Interim Condensed Consolidated Statements of Cash Flow
(in thousand euros)
June 30, 2025 June 30, 2024
------------------------------------------------ ------------- -------------
Net income (loss) (21,344) (24,764)
------------------------------------------------ ------------- -------------
Depreciation and amortization, net 707 1,142
Employee benefits costs 79 145
Change in provision for charges 1,085 (105)
Share-based compensation expense 1,554 1,705
Change in fair value of financial assets (249) (992)
Foreign exchange (gains) losses on financial
assets 1,347 (524)
Change in accrued interests on financial assets (191) (212)
Disposal of property and equipment (scrapping) 20 18
Other profit or loss items with no cash effect 3 26
Operating cash flow before change in working
capital (1) (16,989) (23,561)
------------------------------------------------ ------------- -------------
Change in working capital (14,175) 26,597
Net cash generated from / (used in) operating
activities: (31,164) 3,036
------------------------------------------------ ------------- -------------
Acquisition of property and equipment, net (58) (283)
Purchase of other assets (3) --
Disposal of current financial instruments and
paid interests 7,143 1,215
Interest received on financial assets (108) --
Net cash generated from / (used in) investing
activities: 6,974 932
------------------------------------------------ ------------- -------------
Proceeds from the exercise / subscription of
equity instruments 14,932 93
Repayment of borrowings (4,456) (4,420)
Net cash generated / (used in) from financing
activities: 10,476 (4,327)
------------------------------------------------ ------------- -------------
Effect of the exchange rate changes 1,022 (257)
Net increase / (decrease) in cash and cash
equivalents: (12,692) (616)
------------------------------------------------ ------------- -------------
Cash and cash equivalents at the beginning of
the year: 66,396 70,605
Cash and cash equivalents at the end of the
six-months period: 53,704 69,989
------------------------------------------------ ------------- -------------
(1) Cash flows from operating activities include an amount of EUR0.2 million
of interests paid for the first half of 2025 (EUR1,3 million as of December
31, 2024) and interests received for EUR0,5 million for the first half of 2025
(EUR1,9 million as of December 31,2024).
Revenue and other income
The following table summarizes operating revenue for the periods under review:
In thousands of euros June 30, 2025 June 30, 2024 ------------------------------------------------ ------------- ------------- Revenue from collaboration and licensing agreements 1,671 8,293 Government funding for research expenditures 3,189 4,052 Revenue and other income 4,860 12,345 ------------------------------------------------ ------------- -------------
Revenue from collaboration and licensing agreements
Revenue from collaboration and licensing agreements decreased by EUR6.6 million, to EUR1.7 million for the six months ended June 30, 2025, as compared to revenues from collaboration and licensing agreements of EUR8.3 million for the six months ended June 30, 2024. These revenues mainly result from the partial or entire recognition of the proceeds received pursuant to the agreements with AstraZeneca and Sanofi. They are recognized when the entity's performance obligation is met. They are recognized at a point in time or spread over time according to the percentage of completion of the work that the Company is committed to carry out under these agreements.
The evolution for the first half of 2025 is mainly due to:
-- A EUR2.9 million decrease in revenue related to monalizumab, to EUR0.1
million for the six months ended June 30, 2024, as compared to EUR3.0
million for the six months ended June 30, 2023. This change is mainly due
to the progress of Phase 1/2 trials close to termination.
-- A EUR4.0 million decrease in revenue from the collaboration and
research license agreement signed with Sanofi in 2016. On April 15, 2024,
the Company announced the treatment of the first patient in the Phase 2
dose expansion part of the Sanofi-sponsored clinical trial evaluating NK
Cell Engager SAR443579/ IPH6101 in various blood cancers. Under the terms
of the 2016 agreement, this trial progress triggered a milestone payment
of EUR4.0 million fully recognized in revenue during the first quarter of
2024. This amount was received by the Company on May 17, 2024. The
Sanofi-sponsored Phase 1/2 clinical trial evaluating IPH6401/SAR'514
targeting BCMA in autoimmune indications, is on going. No milestone
payment has been recognized as of June 30, 2025.
Government financing for research expenditures
Government financing for research expenditures decreased by EUR0.9 million, or 21.3%, to EUR3.2 million for the six months ended June 30, 2025 as compared to EUR4.1 million for the six months ended June 30, 2024. This change is mainly due to a EUR0.8 million decrease in the research tax credit due to a decrease in eligible subcontracting expenses.
Operating expenses
The table below presents our operating expenses for the six months periods ended June 30, 2025 and June 30, 2024:
In thousands of euros June 30, 2025 June 30, 2024 ------------------------------------ ------------- ------------- Research and development expenses (20,520) (29,076) General and administrative expenses (9,767) (9,582) ------------------------------------ ------------- ------------- Operating expenses (30,287) (38,657) ------------------------------------ ------------- -------------
Research and development expenses
Research and development ("R&D") expenses decreased by EUR8.6 million, or 29.4%, to EUR20.5 million for the six months ended June 30, 2025, as compared to EUR29.1 million for the six months ended June 30, 2024, representing a total of 67.8% and 75.2% of the total operating expenses, respectively. R&D expenses include direct R&D expenses (subcontracting costs and consumables), depreciation and amortization, personnel expenses and other expenses.
Direct R&D expenses decreased by EUR7.3 million, or 43.1%, to EUR9.7 million for the six months ended June 30, 2025, as compared to EUR17.1 million for the six months ended June 30, 2024. This variation is mainly explained by a EUR7.5 million decrease in expenses related to the phasing of studies (maturity of clinical studies on lacutamab, discontinuation of preclinical studies, and start of phase 1 of our antibody-drug conjugate (ADC) program). Expenditures related to preclinical programs increase by EUR0.2 million.
The variation in clinical program expenses is explained by: (i) a EUR5.8 million decrease in preclinical costs for IPH4502 (drug manufacturing and toxicity studies) following the start of Phase 1; (ii) a EUR2.0 million euros decrease in the Lacutamab program (maturity of clinical studies) (iii) offset by a EUR0.4 million increase related to the IPH 65 program in the recruitment phase.
Additionally, as of June 30, 2025, collaboration liabilities related to monalizumab and the agreements signed with AstraZeneca in April 2015, October 2018, and September 2020 amounted to EUR41.3 million, as compared to collaborations liabilities to EUR48.6 million as of December 31, 2024. This EUR7.3 million decrease mainly results from (i) net reimbursements of EUR1.7 million made to AstraZeneca in the first half of 2025 related to the co-funding of the monalizumab program, including the INTERLINK-1 Phase 3 trial launched in October 2020 and closed as of today and PACIFIC-9 launched in April 2022, and (ii) the decrease in the collaboration commitment by EUR5.6 million due to exchange rate fluctuations observed during the period for the euro-dollar exchange rate.
Personnel and other expenses allocated to R&D decreased by EUR1.2 million, or 10.0%, to EUR10.8 million for the six months ended June 30, 2025, as compared to an amount of EUR12.0 million for the six months ended June 30, 2024. This decrease is attributable to other expenses of EUR1.1 million (primarily a reduction in scientific consulting fees due to the establishment of the clinical department, foreign exchange impacts, and lower patent royalties); (ii) depreciation and amortization charges of EUR0.4 million euros relating to Monalizumab rights following the full amortization of these rights, partially offset by an increase in personnel expenses as a result of the establishment of the clinical department.
General and administrative expenses
General and administrative expenses increased by EUR0.2 million, or 1.9%, to EUR9.8 million for the six months ended June 30, 2025, as compared to general and administrative expenses of EUR9.6 million for the six months ended June 30, 2024. General and administrative expenses represented a total of 32.2% and 24.8% of the total operating expenses for the six months ended June 30, 2025 and June 30, 2024, respectively.
Personnel expenses includes the compensation paid to our employees. They amounted EUR4.8 million for the six months ended June 30, 2025, as compared to EUR4.0 million for the six months ended June 30, 2024. The increase of EUR0.8 million is mainly due to provisions for risks and charges.
Non-scientific and consulting fees mainly consist of fees for statutory auditors, accountants, legal advisors, and recruitment. This item decreased by EUR0.5 million, or 27.8%, to EUR1.4 million for the first half of 2025, compared to EUR1.9 million for the first half of 2024. The decrease is mainly due to greater use of recruitment agencies in 2024 (for the establishment of the clinical department), which was not repeated in 2025.
Other expenses remained stable.
Financial income (loss), net
We recognized a net financial income of EUR4.1 million in the six months ended June 30, 2025 as compared to EUR1.5 million in the six months ended June 30, 2024. This variance of EUR2.5 million mainly results from (i) a favorable variation in net foreign exchange gain increasing by EUR3.9 million for the first half of 2025 with its favorable impact on the collaboration liabilities recorded during the first half of 2025 in connection with the change in the dollar exchange rate and (ii) an unfavorable variation of EUR1.5 million in income resulting from financial assets and fair value revaluation due to an unfavorable effect of investment rates recorded on the financial markets.
Balance sheet items
Cash, cash equivalents, short-term investments and non-current financial assets amounted to EUR70.4 million as of June 30, 2025, as compared to EUR91.1 million as of December 31, 2024. Net cash as of June 30, 2025 amounted to EUR51.1 million (EUR72.1 million as of December 31, 2024). Net cash is equal to cash, cash equivalents and short-term investments less current financial liabilities.
The Company also has bank borrowings of EUR26.4m, including EUR18.1m of State Guaranteed Loans ("Prêts Garantis par l'Etat") as of June 30, 2025 and EUR8.3m loans subscribed with Société Générale for the construction of its head office as well as EUR0.6m of lease liabilities.
The other key balance sheet items as of June 30, 2025 are:
-- Deferred revenue of EUR3.2 million (including EUR2.6 million booked as
'Deferred revenue -- non-current portion') and collaboration liabilities
of EUR41.3 million (including EUR34.5 million booked as 'Collaboration
liabilities - non-current portion') relating to the remainder of the
initial payment received from AstraZeneca not yet recognized as revenue
and the part of the co-financing of the monalizumab program with
AstraZeneca;
-- Receivables from the French government amounting to EUR10.7 million in
relation to the research tax credit for 2024 and the six-month period
ended June 30, 2025.
-- Shareholders' equity of EUR5.1 million, including the net loss of the
period of EUR21.3 million and Sanofi investment for EUR15.0m.
Cash-flow items
As of June 30, 2025, cash and cash equivalents amounted to EUR53.7 million, compared to EUR66.4 million as of December 31, 2024, corresponding in a decrease of EUR12.7 million.
The net cash flow used during the period under review mainly results from the following:
-- Net cash flow generated from operating activities of EUR31.2 million
for the six months ended June 30, 2025 as compared to net cash flows used
by operating activities of EUR3.0 million for the six months ended June
30, 2024. Net cash flow from operating activities for the first half of
2024 notably includes (i) the collection of EUR15.0 million in January
2024 following Sanofi's decision to exercise one of its two license
option for an NK Cell Engager program in solid tumors, derived from the
Company's ANKET(R) (Antibody-based NK Cell Engager Therapeutics) platform,
pursuant to the terms of the research collaboration and license agreement
signed in December 2022, (ii) the collection in May 2024 of EUR4.8
million (including value-added tax) the treatment of the first patient in
the Phase 2 dose expansion part of the Sanofi-sponsored clinical trial
evaluating NK Cell Engager SAR443579/ IPH6101 in various blood cancers
and (iii) the repayment by the French Treasury of the research tax credit
receivable relating to the 2019 financial year for an amount of EUR16.7
million during the first quarter of 2024, as well as the carry-back
receivable for an amount of EUR0.3 million. Restated for these
transactions linked to collaboration agreements and other non-recurring
items such as the CIR refund, net cash flow used in operating activities
for the first half of 2025 decreased by EUR2.6 million as compared to the
first half of 2024. This change mainly results from lower net payments to
suppliers.
-- Net cash flow from investing activities of EUR7.0 million for the six
months ended June 30, 2025, as compared to net cash flow used in
investing activities of EUR0.9 million for the first half of 2024. Net
cash flow from investing activities for the first half of 2025 mainly
composed of a disposal of current financial instruments to meet cash
requirements and partially reinvested up to EUR4 million in term deposits
in order to secure and diversify investments. Net cash flow from
investing activities for the first half of 2024 is mainly composed of a
disposal of a current financial instrument which generated a net cash
collection of EUR1.2 million partially offset by acquisitions of property,
plant and equipment and intangible assets for a net amount EUR0.3
million. The Company has not made any other investments in tangible,
intangible or significant financial assets during the first half of 2025
and 2024.
-- Net cash flow in financing activities for the six months ended June 30,
2025 was EUR10.5 million as compared to net cash flow used in financing
activities of EUR4.3 million the six months ended June 30, 2024, This
cash flow includes the investment for a net amount of EUR14,9 million
received from Sanofi, partially offset by consumptions mainly related to
repayments of financial liabilities for EUR4,4 million (EUR4,3 million
for the six month ended June 30, 2024).
Post period events
-- Innate Pharma plans to prioritize its investment on what it believes
are its highest-value clinical assets, IPH4502, lacutamab, and
monalizumab partnered with AstraZeneca; its preclinical research and
development (R&D) efforts will focus on advancing the next ADCs toward
development, leveraging its pipeline of innovative targets. In line with
such strategic focus and its objectives, the Company intends to
streamline its organization. Staffing levels are expected to decrease
overall by about 30%l, including through attrition. The planned layoffs
will be implemented through a redundancy plan that is subject to
consultation with the Workers' Council and endorsement by the French
authorities (Dreets). The implementation of the change is expected to be
completed during the first half of 2026.
-- Eric Vivier has decided to return to academic research full-time, and
he will continue to support the Company's innovation as an advisor to the
R&D Committee of the Board of Directors. As Chief Operating Officer (COO),
Yannis Morel will continue to be responsible for preclinical research and
development, and will assume Chief Scientific Officer (CSO)
responsibilities.
Nota
The interim condensed consolidated financial statements for the six-month period ended June 30, 2025 were established in accordance with IAS 34 standard adopted by European Union and as issued by the International Accounting Standards Board (IASB). They have been subject to a limited review by our Statutory Auditors and were approved by the Board of Directors of the Company on September 16, 2025. They will not be submitted for approval to the general meeting of shareholders.
Risk factors
Risk factors identified by the Company are presented in the item 3.D of the annual report filed with the SEC (20-F), on April 30, 2025 (SEC Accession No. 0001598599-25-000042). The main risks and uncertainties the Company may face in the six remaining months of the year are the same as the ones presented in the annual report available on the internet website of the Company.
Of note, the risks that are likely to arise during the remaining six months of the current financial year could also occur during subsequent years.
Related party transactions:
Transactions with related parties during the periods under review are disclosed in Note 18 to the interim condensed consolidated financial statements for the period ended June 30, 2025 prepared in accordance with IAS 34.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250916779361/en/
CONTACT:
For additional information, please contact:
Investors Relations
Innate Pharma
Stéphanie Cornen
stephanie.cornen@innate-pharma.fr
Investors
investors@innate-pharma.fr
Media Relations
maarc
Bruno Arabian
bruno.arabian@maarc.fr
Marianne Paul
marianne.paul@maarc.fr
(END) Dow Jones Newswires
September 17, 2025 01:00 ET (05:00 GMT)